
CORT
Corcept Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
70.270
Open
68.150
VWAP
69.62
Vol
874.63K
Mkt Cap
7.41B
Low
67.975
Amount
60.90M
EV/EBITDA(TTM)
61.38
Total Shares
104.11M
EV
6.91B
EV/OCF(TTM)
38.50
P/S(TTM)
11.54
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
199.39M
+21.73%
--
--
247.54M
+35.6%
--
--
294.90M
+62.13%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Corcept Therapeutics Incorporated (CORT) for FY2025, with the revenue forecasts being adjusted by -0.7% over the past three months. During the same period, the stock price has changed by -2.20%.
Revenue Estimates for FY2025
Revise Downward

-0.7%
In Past 3 Month
Stock Price
Go Down

-2.20%
In Past 3 Month
4 Analyst Rating

99.30% Upside
Wall Street analysts forecast CORT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CORT is 139.33 USD with a low forecast of 131.00 USD and a high forecast of 145.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy

99.30% Upside
Current: 69.910

Low
131.00
Averages
139.33
High
145.00

99.30% Upside
Current: 69.910

Low
131.00
Averages
139.33
High
145.00
Piper Sandler
David Amsellem
Buy
Maintains
$128 → $131
2025-04-03
Reason
Piper Sandler
David Amsellem
Price Target
$128 → $131
2025-04-03
Maintains
Buy
Reason
Piper Sandler raised the firm's price target on Corcept Therapeutics to $128 from $78 and keeps an Overweight rating on the shares.
Canaccord Genuity
Edward Nash
Strong Buy
Maintains
$130 → $142
2025-04-01
Reason
Canaccord Genuity
Edward Nash
Price Target
$130 → $142
2025-04-01
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Maintains
$115 → $150
2025-03-31
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$115 → $150
2025-03-31
Maintains
Strong Buy
Reason
Truist Securities
Joon Lee
Strong Buy
Maintains
$76 → $150
2025-03-31
Reason
Truist Securities
Joon Lee
Price Target
$76 → $150
2025-03-31
Maintains
Strong Buy
Reason
Truist analyst Joon Lee raised the firm's price target on Corcept Therapeutics to $150 from $76 and keeps a Buy rating on the shares. The stock in morning trading is up 85%, or $46.48, to $101.11. The company this morning reported positive Phase 3 ROSELLA data, with positive progression free survival and overall survival which looks competitive to that of Elahere's most recent data, the analyst tells investors in a research note. The firm says Corcept plans to submit a new drug application in Q3 with likely approval and launch in 2026 or 2027. It models peak sales of $800M in 2035. Relacorilant's broader opportunity in other solid tumors represent upsides not captured in the model, Truist adds. The drug's "long durability" of intellectual property into the 2040s "gives us more reasons to be constructive," the firm adds.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$115
2025-02-27
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$115
2025-02-27
Reiterates
Strong Buy
Reason
Piper Sandler
David Amsellem
Buy
Maintains
$67 → $78
2025-02-27
Reason
Piper Sandler
David Amsellem
Price Target
$67 → $78
2025-02-27
Maintains
Buy
Reason
Piper Sandler analyst David Amsellem raised the firm's price target on Corcept Therapeutics to $78 from $67 and keeps an Overweight rating on the shares following quarterly results. Looking ahead, the potential approval of relacorilant could render the current debate regarding Korlym exclusivity and exposure to generics as largely irrelevant, Piper adds.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Corcept Therapeutics Inc (CORT.O) is 45.07, compared to its 5-year average forward P/E of 28.29. For a more detailed relative valuation and DCF analysis to assess Corcept Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Strongly Overvalued
5Y Average PE
28.29
Current PE
45.07
Overvalued PE
35.77
Undervalued PE
20.81
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Overvalued
5Y Average EV/EBITDA
18.03
Current EV/EBITDA
28.41
Overvalued EV/EBITDA
23.88
Undervalued EV/EBITDA
12.18
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued
5Y Average PS
5.95
Current PS
7.31
Overvalued PS
7.27
Undervalued PS
4.62
Financials
Annual
Quarterly
FY2025Q1
YoY :
+7.09%
157.21M
Total Revenue
FY2025Q1
YoY :
-88.42%
3.42M
Operating Profit
FY2025Q1
YoY :
-25.99%
20.55M
Net Income after Tax
FY2025Q1
YoY :
-32.00%
0.17
EPS - Diluted
FY2025Q1
YoY :
-78.85%
5.02M
Free Cash Flow
FY2025Q1
YoY :
+0.20%
98.47
Gross Profit Margin - %
FY2025Q1
YoY :
+8.52%
25.85
FCF Margin - %
FY2025Q1
YoY :
-30.88%
13.07
Net Margin - %
FY2025Q1
YoY :
-0.64%
21.77
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
20.1M
USD
26
3-6
Months
37.0M
USD
16
6-9
Months
2.2M
USD
6
0-12
Months
2.3M
USD
9
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
20.1M
USD
26
3-6
Months
37.0M
USD
16
6-9
Months
2.2M
USD
6
0-12
Months
2.3M
USD
9
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CORT News & Events
Events Timeline
2025-06-23 (ET)
2025-06-23
16:31:45
Corcept says Catalyst trial met primary endpoint

2025-06-05 (ET)
2025-06-05
06:04:44
Corcept Therapeutics' dazucorilant did not meet primary endpoint in ALS study

2025-06-02 (ET)
2025-06-02
11:18:02
Corcept Therapeutics says Phase 3 ROSELLA trial met primary endpoint

Sign Up For More Events
Sign Up For More Events
News
6.5
07-24NASDAQ.COMAnalysts Anticipate 14% Upside For VIOO
2.0
07-17NASDAQ.COMMadrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?
9.0
07-14NASDAQ.COMCorcept Submits NDA For Relacorilant To Treat Platinum-Resistant Ovarian Cancer
Sign Up For More News
People Also Watch

LAZ
Lazard Inc
53.130
USD
+0.32%

LFUS
Littelfuse Inc
260.400
USD
+10.44%

UPST
Upstart Holdings Inc
83.325
USD
+3.60%

NWS
News Corp
33.520
USD
-0.15%

LUMN
Lumen Technologies Inc
4.460
USD
-2.83%

VIRT
Virtu Financial Inc
44.790
USD
+1.70%

CMC
Commercial Metals Co
52.190
USD
-0.40%

MC
Moelis & Co
71.160
USD
+0.08%

SQM
Sociedad Quimica y Minera de Chile SA
37.370
USD
-3.74%
FAQ

What is Corcept Therapeutics Inc (CORT) stock price today?
The current price of CORT is 69.91 USD — it has increased 2.51 % in the last trading day.

What is Corcept Therapeutics Inc (CORT)'s business?

What is the price predicton of CORT Stock?

What is Corcept Therapeutics Inc (CORT)'s revenue for the last quarter?

What is Corcept Therapeutics Inc (CORT)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Corcept Therapeutics Inc (CORT)'s fundamentals?

How many employees does Corcept Therapeutics Inc (CORT). have?
